Emma Walmsley Sells 120,653 Shares of GSK plc (LON:GSK) Stock

GSK plc (LON:GSK) insider Emma Walmsley sold 120,653 shares of the firm’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of GBX 1,453 ($18.26), for a total transaction of £1,753,088.09 ($2,203,202.32).

GSK Price Performance

GSK stock opened at GBX 1,444.50 ($18.15) on Friday. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. GSK plc has a 52 week low of GBX 1,282.50 ($16.12) and a 52 week high of GBX 1,823.50 ($22.92). The firm’s fifty day moving average is GBX 1,365.37 and its 200 day moving average is GBX 1,455.35. The firm has a market cap of £58.62 billion, a P/E ratio of 23.33, a P/E/G ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last released its earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.29) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Research analysts predict that GSK plc will post 175.980975 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Berenberg Bank lowered their price objective on shares of GSK from GBX 1,820 ($22.87) to GBX 1,600 ($20.11) and set a “buy” rating on the stock in a research report on Friday, November 29th. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a research report on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of GBX 1,805.83 ($22.69).

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.